Peptide Guides

Fertility Peptides: HCG, HMG, and Kisspeptin Research

PepTracker Pro Research Team February 1, 2026 15 min read

Last reviewed: April 17, 2026

The HPG Axis: Master Control of Reproduction
GnRH Physiology and Pulse Frequency
HCG: A Cornerstone of Fertility Medicine
HCG Clinical Use and Protocols
HMG: Combined Gonadotropin Therapy
FSH vs HMG in Clinical Practice
Kisspeptin: The Master Switch
Kisspeptin-10 in Human Clinical Trials
GnRH Agonist vs Antagonist Approaches
Kisspeptin's Theoretical Advantages
Male Fertility Peptides and Kisspeptin-10 Variants
Oxytocin and Reproductive Health
Integration of Peptide Therapies in Clinical IVF
Important Medical Context

The HPG Axis: Master Control of Reproduction

Fertility is governed by the hypothalamic-pituitary-gonadal (HPG) axis — a hormonal cascade starting in the hypothalamus (deep brain structure) and ending in the reproductive organs (ovaries/testes). The hypothalamus produces and releases gonadotropin-releasing hormone (GnRH) in pulses approximately every 60-90 minutes. GnRH travels to the anterior pituitary gland via blood vessels in the pituitary stalk, stimulating release of two gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH). FSH and LH circulate in blood and act on the ovaries or testes, stimulating gametogenesis (egg or sperm production) and sex steroid synthesis (estradiol, progesterone, testosterone). Sex steroids feed back to regulate GnRH, FSH, and LH secretion. Several peptide-based therapeutics target different points in this exquisitely regulated cascade.

GnRH Physiology and Pulse Frequency

GnRH pulsatility is crucial for normal HPG axis function. Constant, non-pulsatile GnRH paradoxically suppresses gonadotropins (via receptor desensitization), whereas pulsatile GnRH stimulates them. In women, the pulsatile pattern changes across the menstrual cycle: approximately 1 pulse/90 minutes in the follicular phase, accelerating to 1 pulse/60-90 minutes during the luteal phase. In men, pulsatility remains relatively constant at 1 pulse/90 minutes throughout life (assuming health). Disruption of GnRH pulsatility — from stress, excessive exercise, body fat loss, or medications — causes hypogonadotropic hypogonadism (low GnRH/FSH/LH and inadequate testosterone/estradiol). Restoring pulsatile GnRH signaling is fundamental to fertility treatments.

HCG: A Cornerstone of Fertility Medicine

Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone naturally produced by the placental trophoblast during pregnancy, beginning shortly after embryo implantation. HCG mimics LH structurally and functionally, activating LH receptors on Leydig cells (in testes) or theca cells (in ovaries). In fertility medicine, HCG is used extensively for both women and men: In women, HCG triggers final oocyte (egg) maturation and ovulation in assisted reproduction cycles — injected 34-36 hours before planned egg retrieval, HCG induces meiosis II completion and ovulation. In men (particularly during testosterone replacement therapy or after long-term GnRH suppression), HCG stimulates testosterone production and maintains testicular size and spermatogenesis. HCG is FDA-approved as prescription-only, available from pharmaceutical manufacturers with pharmaceutical-grade purity and sterility.

HCG Clinical Use and Protocols

HCG is administered via intramuscular or subcutaneous injection. Typical IVF protocols use a single 'trigger shot' of 250 mcg (recombinant) or 5,000-10,000 IU (urinary-derived HCG). In men on TRT or GnRH agonist therapy, HCG 1,500-5,000 IU is injected 2-3 times weekly to maintain testicular function. Dosing is individualized based on baseline hormone levels, body weight, and clinical response. Serial ultrasound or hormone monitoring (LH, testosterone) guides dose adjustments. HCG remains one of the most-used peptides in fertility medicine globally, with decades of safety data demonstrating acceptable side effect profile at appropriate doses.

HMG: Combined Gonadotropin Therapy

Human Menopausal Gonadotropin (HMG) is an extracted and purified mixture of FSH and LH (approximately 1:1 ratio), derived historically from urine of postmenopausal women (hence the name). Modern recombinant FSH and LH preparations have replaced urinary-derived HMG in most contexts, but the clinical principles remain the same. HMG is used in: controlled ovarian stimulation protocols for IVF (stimulating follicle growth and estradiol production), treatment of male infertility where FSH is deficient (stimulating spermatogenesis), and GnRH-deficient hypogonadism (replacing both FSH and LH). Brand names include Menopur, Repronex, and Fertinorm. HMG provides a more physiologically complete gonadotropin signal than FSH alone, making it valuable when LH support is needed.

FSH vs HMG in Clinical Practice

FSH (follicle-stimulating hormone) alone is sufficient for follicle growth and estradiol production in most IVF cycles. Many protocols use FSH alone for cost and simplicity. However, LH activity (provided by HMG or added hCG) becomes important in certain scenarios: (1) older women whose ovarian sensitivity to FSH declines, (2) normal men requiring spermatogenesis support (FSH is required but LH stimulates testosterone, which supports spermatogenesis), (3) GnRH-deficient patients needing both FSH and LH replacement. Adding LH (via HMG or direct LH injections) improves outcomes in some but not all patients, making it a treatment decision that reproductive endocrinologists individualize.

Kisspeptin: The Master Switch

Kisspeptin is a neuropeptide encoded by the KISS1 gene, discovered in 2003 as a critical regulator of puberty and reproduction. Kisspeptin-producing neurons in the hypothalamus directly synapse onto GnRH neurons, exciting them and triggering GnRH pulses. Kisspeptin is considered the 'gatekeeper' of reproduction — it integrates multiple physiological signals (body energy status, stress, photoperiod) and translates them into GnRH pulses. Loss-of-function mutations in KISS1 or its receptor (GPRC141) cause hypogonadotropic hypogonadism and infertility. Restoration of kisspeptin signaling can trigger GnRH secretion in kisspeptin-deficient patients. Kisspeptin represents a potentially more physiological approach to fertility treatment than exogenous gonadotropins.

Kisspeptin-10 in Human Clinical Trials

Kisspeptin-10 (a 10-amino acid fragment of the full 145-amino acid peptide) has been studied in multiple Phase 1 and Phase 2 clinical trials. One landmark study showed that a single intravenous kisspeptin-10 infusion reliably triggered LH surges in women, demonstrating its ability to activate GnRH neurons. Another study showed that repeated kisspeptin-10 dosing (via subcutaneous injection) maintained elevated LH and FSH levels. Early IVF protocols using kisspeptin to trigger final oocyte maturation (instead of hCG) have shown promise with comparable oocyte maturation rates and potentially fewer ovarian hyperstimulation syndrome (OHSS) cases. However, clinical trials are still preliminary — larger trials are needed to establish safety/efficacy and determine if kisspeptin offers advantages over established protocols.

GnRH Agonist vs Antagonist Approaches

GnRH agonists (long-acting GnRH analogs like leuprolide, goserelin) are used in fertility protocols to suppress endogenous GnRH signaling, preventing premature LH surge during ovarian stimulation. GnRH antagonists (like ganirelix, cetrorelix) block GnRH receptors directly, also preventing premature LH surge but with faster kinetics. Both are FDA-approved for IVF. The difference: GnRH agonists cause initial GnRH receptor stimulation (flare effect), then downregulation and suppression. GnRH antagonists immediately block receptors without flare. GnRH antagonist cycles are shorter and may cause fewer side effects. The choice between agonist and antagonist is individualized by reproductive endocrinologists based on patient age, ovarian reserve, and prior response to stimulation.

Kisspeptin's Theoretical Advantages

Compared to exogenous gonadotropins, kisspeptin might: (1) trigger more physiological GnRH pulses, potentially improving reproductive outcomes, (2) reduce hyperstimulation risk by using endogenous FSH/LH responses rather than pharmacologically amplifying them, (3) provide a treatment option for GnRH-deficient infertility, restoring the upstream signal rather than bypassing it. However, these advantages remain largely theoretical — large clinical trials demonstrating superior outcomes are lacking. Kisspeptin development is proceeding slowly, likely because pharmaceutical companies are less interested in developing novel fertility treatments compared to metabolic or cardiovascular drugs.

Male Fertility Peptides and Kisspeptin-10 Variants

For male infertility, HCG is the primary hormone therapy, stimulating testosterone and spermatogenesis. Kisspeptin may become relevant for men with hypogonadotropic hypogonadism (low GnRH, low FSH/LH, low testosterone and sperm count). Kisspeptin-10 variants and higher-potency kisspeptin analogs are in development, potentially offering better receptor selectivity or longer duration of action. Some research explores combinations: GnRH + additional kisspeptin signaling might produce more robust spermatogenesis recovery than GnRH alone. However, current male fertility treatment remains dominated by HCG and FSH — kisspeptin remains research-stage.

Oxytocin and Reproductive Health

Oxytocin is a nine-amino acid peptide produced by magnocellular neurons in the hypothalamus, released by the posterior pituitary. Oxytocin has roles in: uterine contractions during labor and orgasm, milk letdown during lactation, and maternal-infant bonding. During IVF, oxytocin is sometimes used in protocols to support uterine contractions during embryo transfer, though evidence for benefit is mixed. Intranasal oxytocin is being researched for broader neuropsychiatric applications (autism, social function, stress), though reproductive uses remain its most established clinical indication. Oxytocin does not directly regulate fertility (unlike GnRH or gonadotropins), but it supports reproductive function secondarily.

Integration of Peptide Therapies in Clinical IVF

Modern IVF protocols integrate multiple peptide hormones: GnRH agonist or antagonist (suppresses endogenous GnRH), FSH ± LH (stimulates follicle growth and steroidogenesis), HCG trigger (mimics LH surge, triggers ovulation), and potentially oxytocin support during embryo transfer. This polypharmacy is complex and requires careful coordination by experienced reproductive endocrinologists. The goal is to synchronize follicle development, prevent premature ovulation, trigger final egg maturation at exactly the right moment, and retrieve viable mature oocytes. Understanding how each peptide works in this integrated system is essential for informed discussions with fertility clinicians.

Important Medical Context

Fertility treatments are complex medical interventions requiring careful monitoring by reproductive endocrinologists. HCG and HMG are prescription medications with specific protocols, dosing schedules, and monitoring requirements (ultrasound, serum hormones). Common side effects include ovarian hyperstimulation syndrome (OHSS, ranging from mild bloating to life-threatening fluid accumulation), injection site reactions, and mood changes. Kisspeptin remains primarily a research compound, not yet available clinically. Self-treatment with any fertility-related peptide or hormone is strongly discouraged — these are powerful biological signals that require professional medical oversight, individualized protocols, and close monitoring for safety and efficacy. Seek care from board-certified reproductive endocrinologists.

Ready to track your peptide research?

Open PepTracker Pro

PepTracker Pro Research Team

The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.

Citations

[1] Lunenfeld B — Historical perspectives in gonadotrophin therapy, Hum Reprod Update 2004 Source
[2] Dhillo WS et al. — Kisspeptin-54 stimulates gonadotropin release, JCEM 2005 Source
[3] Horikoshi Y et al. — GnRH and kisspeptin: Physiological roles and therapeutic potential, Endocrinology 2010 Source
[4] Caronia LM et al. — Abrupt GnRH withdrawal in healthy women, J Clin Endocrinol Metab 2013 Source

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. Read full research disclaimer →